Compare MRCC & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRCC | IPSC |
|---|---|---|
| Founded | 2011 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.2M | 49.8M |
| IPO Year | 2012 | 2021 |
| Metric | MRCC | IPSC |
|---|---|---|
| Price | $6.33 | $0.67 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $8.00 | $3.00 |
| AVG Volume (30 Days) | 93.3K | ★ 840.4K |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | ★ 15.77% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $43,742,000.00 | ★ $113,337,000.00 |
| Revenue This Year | N/A | $1,590.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 4122.69 |
| 52 Week Low | $5.86 | $0.34 |
| 52 Week High | $8.85 | $1.26 |
| Indicator | MRCC | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 39.87 | 70.42 |
| Support Level | $6.65 | $0.54 |
| Resistance Level | $6.80 | $0.62 |
| Average True Range (ATR) | 0.15 | 0.04 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 17.29 | 89.83 |
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.